Search | Clinical Trials Finder

Conditions: Glycemic Control
Interventions: Fasiglifam (TAK-875), Sitagliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Diabetes Mellitus Type 2
Interventions: DPP-IV Inhibitor, Metformin, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Concord, California • Salinas, California • San Diego, California + 17 more

Conditions: Diabetes, Pregnancy
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Jackson, Mississippi + 7 more

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Type 2 Diabetes
Interventions: exenatide, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 109
States / cities: Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Healthy Subjects
Interventions: E5555; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Overweight or Obesity, Type2 Diabetes Mellitus
Interventions: GSBR-1290, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Anaheim, California • Chula Vista, California • Miami, Florida + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Obesity, Metabolic Syndrome X
Interventions: Metformin, Orlistat, Topiramate, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 40 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions: Metformin, Placebo, Jynneos, Capvaxvie; Drug · Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Metformin, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 72
States / cities: Phoenix, Arizona • Anaheim, California • Fresno, California + 63 more

Conditions: IPMN, IPMN, Pancreatic
Interventions: Sulindac 400 MG, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: KD026, Placebo, Metformin; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more

Conditions: Prediabetic State, Atherosclerosis, Metformin
Interventions: Metformin XR, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 7,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 70 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: La Jolla, California • Norwalk, California • Miami, Florida + 10 more

Conditions: Covid19
Interventions: Placebo, Metformin; Other · Drug
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 3,214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Diabetes
Interventions: Saxagliptin, Metformin, Placebo, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Concord, California • Encinitas, California • Orange, California + 38 more

Search by objective public record fields.

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Limiting AAA With Metformin (LIMIT) Trial

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise